Becton, Dickinson and Company (BD) announced that its Revello™ Vascular Covered Stent has received CE Marking, allowing the device to be marketed across the European Union and European Economic Area. The stent is a self‑expanding nitinol device with an ultrathin expanded polytetrafluoroethylene covering, designed to treat atherosclerotic lesions in the common and external iliac arteries. It features compliant stent ends to reduce trauma to healthy vessel segments, tantalum radiopaque markers for clear fluoroscopic visualization, and a tri‑axial delivery system that provides precise placement and a low‑profile platform.
The CE approval is a significant regulatory milestone for BD’s peripheral vascular portfolio, but it comes amid a mixed financial picture. In the first quarter of fiscal 2026, BD reported revenue of $5.3 billion, a modest 1.6% increase year‑over‑year, and adjusted diluted earnings per share of $2.91, beating analyst estimates of $2.81. However, the company’s adjusted EPS fell 15.2% from the prior year, and its operating margin contracted by 240 basis points, reflecting pricing pressure and higher operating costs in some segments.
Rima Alameddine, worldwide president of BD Interventional – Peripheral Intervention, said the CE Marking “is a significant advancement toward helping physicians treat complex iliac artery disease. The Revello™ Vascular Covered Stent was built to raise the standard of iliac artery revascularization, expand the growing BD peripheral vascular portfolio, and reinforce the company’s commitment to delivering clinically relevant innovation for physicians treating complex PAD across EU and EEA countries.”
The Revello stent’s development is supported by the AGILITY investigational device exemption study, which is evaluating its safety and effectiveness in patients with peripheral artery disease. Full enrollment of the iliac artery patient cohort has been achieved, positioning BD to collect robust clinical data that will support future regulatory submissions and market adoption.
While the CE Marking is a positive product‑level milestone, it was not a primary driver of market reaction for BD. Investors and analysts focused on the company’s broader financial performance, margin trends, and the ongoing strategic transformation that includes the separation of its Life Sciences & Diagnostic Solutions segment. The announcement underscores BD’s commitment to expanding its peripheral vascular offerings, but the company’s overall trajectory remains influenced by margin compression and modest growth in other business lines.
The competitive landscape for vascular covered stents in the EU is intense, with several established players offering similar devices. BD’s Revello stent differentiates itself through its ultrathin covering, compliant ends, and advanced delivery system, which may provide a clinical advantage in complex iliac artery lesions. However, the market remains highly competitive, and BD will need to demonstrate clear clinical and economic benefits to capture significant market share.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.